Literature DB >> 14753294

The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma.

Magdalena Birker-Robaczewska1, Céline Boukhadra, Rolf Studer, Célia Mueller, Christoph Binkert, Oliver Nayler.   

Abstract

Urotensin-II (U-II) was identified as the natural ligand of the G protein-coupled receptor GPR14, which has been correspondingly renamed Urotensin-II receptor (U2R). The tissue distribution of U2R and the pharmacological effects of U-II suggest a novel neurohormonal system with potent cardiovascular effects. We here report the human rhabdomyosarcoma cell line TE-671 as the first natural and endogenous source of functional U2R in an immortalized cell line. In TE-671 cells, U-II stimulated extracellular signal regulated kinase phosphorylation and increased c-fos mRNA expression. Furthermore, we demonstrate that the expression of U2R mRNA and functional U-II high affinity binding sites are serum-responsive and that they are specifically up-regulated by interferon gamma (IFNgamma). We propose that IFNgamma contributes to the previously observed increase of U2R density in the heart tissue of congestive heart failure (CHF) patients and we suggest that U2R up-regulation, as a consequence of an inflammatory response, could lead to a clinical worsening of this disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14753294     DOI: 10.1081/rrs-120026972

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  9 in total

1.  Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease.

Authors:  San Bao Chai; Xue Min Li; Yong Zheng Pang; Yong Fen Qi; Chao Shu Tang
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

2.  Urotensin II stimulates plasma extravasation in mice via UT receptor activation.

Authors:  Raffaella Vergura; Valeria Camarda; Anna Rizzi; Martina Spagnol; Remo Guerrini; Girolamo Calo'; Severo Salvadori; Domenico Regoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-23       Impact factor: 3.000

3.  Effects of urotensin-II on cytokines in early acute liver failure in mice.

Authors:  Liang-Ming Liu; Liang Zhao; Dong-Yu Liang; Fang-Ping Yu; Chang-Gen Ye; Wen-Juan Tu; Tong Zhu
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

4.  Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF-κB pathway in tumor-bearing nude mice.

Authors:  Cheng-Hua Zhou; Ya-Ya Wan; Xiang-Hua Chu; Zheng Song; Shu-Hua Xing; Yu-Qing Wu; Xiao-Xing Yin
Journal:  Oncol Lett       Date:  2012-09-21       Impact factor: 2.967

5.  Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure.

Authors:  Ludger Leifeld; Christoph Clemens; Jörg Heller; Jonel Trebicka; Tilman Sauerbruch; Ulrich Spengler
Journal:  Dig Dis Sci       Date:  2009-07-07       Impact factor: 3.199

6.  The UII/UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-κB pathways in LPS-stimulated Kupffer cells.

Authors:  Liang Ming Liu; Dong Yu Liang; Chang Gen Ye; Wen Juan Tu; Tong Zhu
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

Review 7.  The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.

Authors:  Hélène Castel; Laurence Desrues; Jane-Eileen Joubert; Marie-Christine Tonon; Laurent Prézeau; Marie Chabbert; Fabrice Morin; Pierrick Gandolfo
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-25       Impact factor: 5.555

8.  DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells.

Authors:  Vishakha Sharma; Naoe Harafuji; Alexandra Belayew; Yi-Wen Chen
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

9.  Inhibition of UII/UTR system relieves acute inflammation of liver through preventing activation of NF-κB pathway in ALF mice.

Authors:  Dong-yu Liang; Liang-ming Liu; Chang-gen Ye; Liang Zhao; Fang-ping Yu; De-yong Gao; Ying-ying Wang; Zhi-wen Yang; Yan-yan Wang
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.